PRISM BioLab Co.

PRISM BioLab Co., Ltd., is a biotechnology company with a proprietary small molecule drug discovery platform "PepMetics™ Technology". The PepMetics™ molecules are designed to mimic -helix or -turn peptides using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using this small molecule technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed. Further, PRISM BioLab is working on new drug targets in collaboration with Global and Japanese pharmaceutical companies.